GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corestemchemon Inc (XKRX:166480) » Definitions » Shiller PE Ratio

Corestemchemon (XKRX:166480) Shiller PE Ratio : (As of May. 14, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Corestemchemon Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Corestemchemon Shiller PE Ratio Historical Data

The historical data trend for Corestemchemon's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corestemchemon Shiller PE Ratio Chart

Corestemchemon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corestemchemon Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corestemchemon's Shiller PE Ratio

For the Biotechnology subindustry, Corestemchemon's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corestemchemon's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corestemchemon's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Corestemchemon's Shiller PE Ratio falls into.


;
;

Corestemchemon Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Corestemchemon's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Corestemchemon's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=203/121.1352*121.1352
=203.000

Current CPI (Dec. 2024) = 121.1352.

Corestemchemon Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -46.000 99.721 -55.878
201506 17.000 100.051 20.583
201509 5.000 100.111 6.050
201512 -18.000 100.220 -21.756
201603 -49.000 100.561 -59.025
201606 -24.000 100.791 -28.844
201609 40.000 101.461 47.756
201612 -73.000 101.561 -87.069
201703 -57.000 102.851 -67.133
201706 -39.000 102.611 -46.040
201709 -39.000 103.491 -45.649
201712 -121.000 102.991 -142.317
201803 -7.000 104.101 -8.145
201806 -81.000 104.130 -94.228
201809 -18.000 105.651 -20.638
201812 -109.000 104.351 -126.532
201903 -37.000 104.491 -42.894
201906 -20.000 104.881 -23.100
201909 -65.000 105.200 -74.846
201912 -207.000 105.121 -238.534
202003 -66.000 105.354 -75.886
202006 -68.000 105.112 -78.366
202009 -183.000 106.198 -208.741
202012 -1,158.000 105.765 -1,326.280
202103 532.000 107.357 600.276
202106 -1,160.000 107.579 -1,306.178
202109 -175.000 108.759 -194.914
202112 159.000 109.676 175.612
202203 -139.000 111.848 -150.542
202206 1.000 114.072 1.062
202209 -528.000 114.715 -557.549
202212 -68.000 115.179 -71.516
202303 -128.000 116.507 -133.084
202306 -268.000 117.182 -277.041
202309 -219.000 118.964 -222.998
202312 -364.000 118.837 -371.039
202403 -518.000 120.123 -522.364
202406 -622.000 120.007 -627.846
202409 -198.000 120.861 -198.449
202412 203.000 121.135 203.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corestemchemon  (XKRX:166480) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Corestemchemon Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Corestemchemon's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corestemchemon Business Description

Traded in Other Exchanges
N/A
Address
Pangyo 255 beongil 24 I & C Building, 2nd Floor, yeonggi-do, Bundang-gu, Seongnam, Seoul, KOR, 13486
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.

Corestemchemon Headlines

No Headlines